MEDI1341

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Parkinson's Disease

Phase 1

Single Ascending Dose Study of MEDI1341 in Healthy Volunteers

CompletedNCT03272165

AstraZenecaParkinson's Disease

Start: 2017-10-17End: 2021-03-31Updated: 2022-06-09

Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease

CompletedNCT04449484

AstraZenecaParkinson's Disease

Start: 2020-08-04End: 2022-01-05Updated: 2022-06-03

Related Papers

Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free α-synuclein lowered by >50.

2025-08-19

Reducing α-Synuclein in Human CSF; An Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1341, an α-Synuclein-specific antibody, in Healthy Volunteers and Parkinson’s Disease Patients (P1-11.007)

Neurology2023-04-259 citations

Study Design of TAK-341-2001: A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-341 in Subjects With Multiple System Atrophy (P9-9.003)

Neurology2023-04-253 citations